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Abstract
Background: Cytomegalovirus (CMV) is the most frequent cause of congenital infection. The objective of this study was to
evaluate predictive factors for CMV seronegativity in a cohort of pregnant women in Paris, France.
Methods: Pregnant women enrolled in a prospective cohort during the 2009 A/H1N1 pandemic were tested for CMV IgG
antibodies. Variables collected were age, geographic origin, lifestyle, work characteristics, socioeconomic status, gravidity,
parity and number of children at home. A multivariate logistic regression model was used to identify independent
predictive factors for CMV seropositivity.
Results: Among the 826 women enrolled, 389 (47.1%) were primiparous, and 552 (67.1%) had Metropolitan France as a
geographic origin. Out of these, 355 (i.e. 57.0%, 95% confidence interval (CI): [53.6%–60.4%]) were CMV seropositive: 43.7%
(95% CI:[39.5%–47.9%]) in those whose geographic origin was Metropolitan France and 84.1% in those with other origins
(95% CI:[79.2%–88.3%]). Determinants associated with CMV seropositivity in a multivariate logistic regression model were:
(i) geographic origin (p,0.001(compared with Metropolitan France, geographic origins of Africa adjusted odds ratio (aOR)
21.2, 95% CI:[9.7–46.5], French overseas departments and territories and other origin, aOR 7.5, 95% CI:[3.9–14.6], and Europe
or Asia, aOR 2.2, 95% CI: [1.3–3.7]); and (ii) gravidity (p = 0.019), (compared with gravidity = 1, if gravidity$3, aOR= 1.5, 95%
CI: [1.1–2.2]; if gravidity = 2, aOR= 1.0, 95% CI: [0.7–1.4]). Work characteristics and socioeconomic status were not
independently associated with CMV seropositivity.
Conclusions: In this cohort of pregnant women, a geographic origin of Metropolitan France and a low gravidity were
predictive factors for CMV low seropositivity. Such women are therefore the likely target population for prevention of CMV
infection during pregnancy in France.
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Introduction
Cytomegalovirus (CMV) is the most frequent cause of
congenital infection in high-income countries. Approximately
1% of all newborns are infected by CMV at birth [1]. Of those
infected, 10% are symptomatic and at high risk of developing
permanent neurological or motor impairment, deafness, and
blindness [2–5]. Among asymptomatic infected newborns, 5–10%
will develop progressive hearing loss [2,6,7].
Primary and recurrent CMV infections have been observed
during pregnancy [1,3]. The risk of congenital infection is higher
after maternal primary infection than after recurrent infection [1].
In France, as in most developed countries, around 50% of women
of childbearing age are susceptible to CMV infection [8–11]. In
CMV seronegative women, a 30% fetal transmission rate can be
observed following primary infection during pregnancy [12].
Routine screening of women susceptible to CMV during
pregnancy is controversial and not recommended in France, but
the French National Institute for Public Health Surveillance
(InVS) has estimated that 300,000 serodiagnostic tests are
performed each year (2004 data), leading to costs and pregnan-
cy-related stress (www.invs.sante.fr/publications/2007/
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cmv_grossesse). Routine screening is controversial because of
scarce knowledge of the natural history of the disease, incomplete
epidemiological data, and the fact that health interventions are
limited and not consensual. It has, however, been stated that
hygiene information on how to prevent CMV primary infection
during pregnancy should be promoted, especially in CMV
seronegative women [13]. Moreover, clinical trials on CMV
vaccine candidates are promising, with several vaccine candidates
at different stages of testing. In 2009, Pass et al reported promising
results from a Phase II trial of one of these candidate vaccines
demonstrating around 50% (95% CI: [7%–73%]) efficacy in
preventing maternal primary infection [14]. With the potential
arrival of new vaccines against CMV infection, there is an
increased need to identify CMV seronegative non-pregnant
women in order to prevent seroconversion during pregnancy.
While the vaccine has yet not been tested on women with a pre-
existing immunity, it is reasonable to believe that it could also help
to prevent re-infection or reactivation. However, seropositive and
seronegative women will probably not benefit from vaccination
against CMV at the same extent since the risk of fetal transmission
during pregnancy is reduced by the mother immunity [1].
Therefore the characterization of a target population of the
vaccine could allow a more effective intervention.
Several studies have evaluated major determinants associated
with seroprevalence, but none are recent enough to reflect current
CMV epidemiology in France with a view to implementing an
immunization campaign [10]. This study aims to characterize
women susceptible to primary infection that would actually benefit
from immunization campaign against CMV, and to assess in the
French specific context, the predictive factors that would allow
their identification.
Materials and Methods
Participants
The COFLUPREG ‘‘COhort on Flu during PREGnancy’’
study was a prospective cohort study conducted in pregnant
women in three tertiary maternity centers in Paris (France) during
the 2009 A/H1N1 influenza pandemic. 919 pregnant women
randomly selected in order to obtain a representative sample of
pregnant women followed up in these maternity hospitals were
included from October 12, 2009 to February 3, 2010 to assess the
incidence of serious forms of A/H1N1 influenza [15,16]. Blood
samples were obtained at inclusion in the cohort (between 6 and
35 weeks of gestation). Women.18 years old, understanding
French were eligible to participate. Exclusion criteria were
previous vaccination against the 2009 pandemic A/H1N1
influenza or virologically documented A/H1N1 influenza during
the last 6 months. Sociodemographic (maternal age, geographic
origin which includes ethnicity), lifestyle (single or couple) and
obstetrical characteristics were collected at inclusion from medical
records. Stored frozen serum from 826 of the women was
available.
Some of the data collected were of interest for targeting
pregnant women susceptible to CMV: sociodemographic charac-
teristics, socioeconomic status (based on French National Institute
for Statistics and Economic Studies (INSEE) nomenclatures for
socioprofessional categories (http://www.insee.fr/nomenclatures),
obstetrical characteristics (gravidity including the present preg-
nancy; parity excluding the present pregnancy) and factors
associated with a higher risk of viral exposure and disease
spreading (number of children,18 years old at home, work in
contact with children and healthcare workers).
Written informed consent was obtained from each woman
before enrolment. The protocol was conducted in accordance with
the Declaration of Helsinki and French law for biomedical
research and was approved by the ‘‘Ile-de-France 3’’ Ethics
Committee (Paris, France). This study was not conducted outside
of France and is registered with ClinicalTrials.gov:
NCT01192737.
Laboratory Methods of Titration to Determine CMV
Seroprevalence
CMV IgG antibody levels were measured by ELISA using ETI-
CYTOK-IgG Plus, Diasorin, Saluggia, Italy. CMV seropositivity
was defined as a serum titer.400 IU/L.
Statistical Methods
For each variable, the choice of the reference class was the one
known to have the lowest CMV seropositivity rate and was made
in accordance with the medical literature. When the literature
lacked this information, the reference was the class with the highest
number of women. Univariate analysis was done using the Chi2
test or Fisher’s exact test when class frequency was,5. The
Cochran-Armitage test was used to test for trends.
Associations between determinants and CMV seroprevalence
were analyzed using univariate analysis. Determinants with a p-
value,0.20 on univariate analysis were included in the logistic
regression model. A systematic search was made for interaction
between determinants included. Then a backward elimination
procedure and a model selection with the Akaike information
criterion (AIC) was used to select the final multivariate model with
factors associated significantly and independently with CMV
seropositivity. Results were expressed as crude and adjusted odds
ratios (aORs) with their 95% confidence interval (95% CI).
Analyses were performed only for patients without missing data
(complete case analysis) with SAS software version 9.3 (SAS
Institute, Cary, NC).
Results
Study Population
Demographic profiles and clinical characteristics of the 826
women screened for CMV IgG are described in Table 1. Median
age was 32.7 years (min: 18.8; max: 49.1), 47.1% of the women
were primiparous, 67.1% had Metropolitan France as a
geographic origin. The cohort had mainly a high (45.9%) or
middle (40.2%) socioeconomic status; 6.7% of the women were
single. The proportion of CMV seropositive women was 57.0%
(95% CI: [53.6%–60.4%]). The proportion was 43.7% (95% CI:
[39.5%–47.9%]) for women whose geographic origin was Metro-
politan France, and 84.1% (95% CI: [79.2%–88.3%]) for those
with other origins.
Univariate Analysis
Sociodemographic and obstetrical determinants significantly
associated with CMV seropositivity were maternal age (p = 0.027),
geographic origin (p,0.001), lifestyle (p = 0.001), socioprofessional
category (p,0.001), gravidity (p,0.001), and parity (p = 0.015)
(Table 1). No significant association was found between CMV
seropositivity and job characteristics (p = 0.271) or number of
children,18 years old at home (p = 0.058), although this factor
was borderline significant.
Seropositivity for CMV decrease with socioeconomic status and
increased when gravidity, parity, or number of children,18 years
old at home increased (p,0.050). CMV seropositivity rate was the
lowest for women whose geographic origin was Metropolitan
CMV Seropositivity in Pregnant Women
PLOS ONE | www.plosone.org 2 February 2014 | Volume 9 | Issue 2 | e89857
France than for those of Europe or Asia; the highest proportion
was observed for women with Sub-Saharan and North Africa
origins (p,0.001). The seropositivity rate was higher in younger
women (64.2%) and decrease for women in the 30–34 and 35–39
age groups (52.8% and 53.6%, respectively). However, women$
40 had a seropositivity of 63.5%, so no linear trend was observed
between age and seropositivity.
Multivariate Logistic Regression
Determinants independently associated with CMV seropositiv-
ity were geographic origin (p,0.001) (compared with Metropol-
itan France, geographic origins of Africa adjusted odds ratio (aOR)
21.2, 95% CI:[9.7–46.5], French overseas departments and
territories and other origin, aOR 7.5, 95% CI:[3.9–14.6], and
Europe or Asia, aOR 2.2, 95% CI:[1.3–3.7]); and gravidity
Table 1. Characteristics of the study population and determinants associated with seropositivity for CMV: univariate analysis.
Variables Total
Seropositive for
CMV Crude OR p-value {
n=826 n=471 [95% CI]
Maternity hospital
Saint-Vincent de Paul 234 56.8% 1.2 [0.9–1.9]
Port-Royal 396 60.1% 1.4 [1.0–2.0]
Necker Brune 196 51.0% 1 0.001
Age, years
15–29 190 64.2% 1
30–34 322 52.8% 0.6 [0.4–0.9]
35–39 207 53.6% 0.6 [0.4–1.0]
$40 107 63.5% 1.0 [0.6–1.6] 0.027
Geographic origin*
Metropolitan France 552 43.7% 1
European, Asian 66 62.1% 2.1 [1.3–3.6]
Sub-Saharan African, North African 129 94.6% 22.5 [10.3–49.0]
French overseas departments and territories, Other 76 85.5% 7.6 [3.9–14.8] ,0.001
Socioprofessional category**
Low 114 73.7% 2.8 [1.8–4.5]
Middle 332 59.3% 1.5 [1.1–2.0]
High 379 49.9% 1 ,0.001{{
Work at risk of CMV infection¥
No 389 55.0% 1
Yes 437 58.8% 0.9 [0.7–1.1] 0.271
Lifestyle**
Single 55 78.2% 2.9 [1.4–5.5]
Couple 770 55.4% 1 0.001
Gravidity
1 268 50.7% 1
2 252 52.4% 1.1 [0.8–1.5]
$3 206 66.3% 1.9 [1.4–2.7] ,0.001{{
Parity
0 389 52.4% 1
1 298 58.7% 1.3 [1.0–1.8]
$2 139 66.2% 1.8 [1.2–2.7] 0.015{{
Number of children ,18 years old at home
0 399 52.9% 1
1 290 60.0% 1.3 [1.0–1.8]
$2 137 62.8% 1.5 [1.0–2.2] 0.058{{
{Chi 2.
{{Cochran-Armitage for trend with p,0.050.
¥ Work at risk included health care workers and job in contact with children.
*3 missing values.
**1 missing value.
doi:10.1371/journal.pone.0089857.t001
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(p = 0.019) (compared with gravidity = 1, if gravidity$3,
aOR=1.5, 95% CI:[1.1–2.2]; if gravidity = 2, aOR=1.0, 95%
CI:[0.7–1.4]) (Table 2).
Discussion
Data from the COFLUPREG prospective cohort allow us to
study numerous determinants associated with CMV seropositivity
and their relative importance. The study was multicentric
involving three major university maternity hospitals in Paris in
2009 and a large number of blood samples recently and randomly
collected was available (n = 826). This study design and the quality
of the data reinforce the reliability of the results.
To our knowledge, in France, or in other West European
countries, no other recent results on the characterization of
women susceptible to CMV infection that highlight, like in this
study, the discrepancy of seroprevalence between women of
African origin and those of French origin. Paris Metropolitan area,
even if not representative of all French population, is an area with
a high proportion of immigrants from sub-Saharan Africa and
their children. Consequently, this study allowed us to specifically
explore CMV in this population. Even if seroprevalence point
estimates from this study cannot be extrapolated to other regions
in France, they are valid and indicative of the fact that CMV
epidemiology is very different among women of African origin
living in France compared to other sub-groups and the overall
population.
These results may be valuable when candidate vaccines against
CMV are tested to identify the population for which vaccination
should be recommended.
However, this study also presents several limitations. First, the
primary objective of the cohort was not linked to study of CMV
infection. Therefore, several determinants associated with CMV
seropositivity were not collected. This was the case, for example, of
sexual behavior, although sexual transmission of CMV from a
sexual partner is well known to be an infection route [17]. It could
also be the reason why the number of children was not found to be
associated with CMV seropositivity since studies have shown that
mothers are mainly infected after contact with very young children
(more likely under 36 months), whereas in Coflupreg the variable
included also women with older children [18].
Second, our study population comes from three university
maternity hospitals in Paris; it is therefore not representative of all
French pregnant women. Thus, compared with the general
population of Metropolitan France in 2009, maternal age during
pregnancy of our study population was higher (32.7 vs. 29.9), as
was the proportion of primiparous women (47.1% vs. 44%), and
high socioeconomic status was more represented at the expense of
middle socioeconomic status (INSEE 2009 http://www.insee.fr/
fr/Donne´es statistiques naissances 2009).
All the pregnant women enrolled came from an urban area
which might have had an impact on seropositivity rate since it has
been shown that women from a rural area tend to have a higher
seropositivity rate [18]. Gratacap et al have shown that place of
birth also has an impact on CMV seroprevalence, with a North-
South gradient even within France, with women born in the
southern regions having a higher seropositivity rate [10,19].
Consequently, results such as the CMV seropositivity and
distribution of sociodemographic factors cannot be extrapolated to
all French pregnant women. But, this limitation probably does not
interfere with the analysis of associations between studied
determinants and CMV seropositivity among pregnant women.
In this cohort of French pregnant women conducted during the
2009 A/H1N1 pandemic, seropositivity for CMV was 57.1%.
Metropolitan France as a geographic origin and a low gravidity
were the predictive factors for low CMV seropositivity. Seropos-
itivity was slightly lower than the rate reported in previous French
studies on pregnant women: 50.1% in the 2009 study by Vauloup-
Fellous et al [9], 44.6% in the 2000 study by Gouarin et al [11]
and 51.5% in the 1998 study by Gratacap-Cavallier et al [10].
This could be due to the high proportion of women of African
origin (16% vs. 6% in the Gratacap-Cavallier et al study, for
example). Pregnant women whose geographic origin was Metro-
politan France had a seropositivity rate of 43%, which was close to
the range (41% to 59%) reported in other high income countries
[20–24].
In the present study, seropositivity rate significantly increased
with increase in parity, gravidity, number of children,18 years
Table 2. Determinant associated with seropositivity for CMV: multivariate analysis including all determinants with a p-value,0.20
in the univariate analysis.
Variables Adjusted OR p-value{
[95% CI]
Geographic origin*
Metropolitan France 1
European, Asian 2.2 [1.3–3.7]
Sub-Saharan African, North African 21.2 [9.7–46.5]
French overseas departments and territories, Other 7.5 [3.9–14.6] ,0.001
Gravidity
1 1
2 1.0 [0.7–1.4]
$3 1.5 [1.1–2.2] 0.019
CI: Confidence Interval.
{Chi 2.
Variables with a p-value,0.20 in univariate analysis were included in the multivariate analysis.
Final logistic regression model was obtained with a backward elimination and with comparison of the Akaike Information Criterion (AIC).
*3 missing values.
doi:10.1371/journal.pone.0089857.t002
CMV Seropositivity in Pregnant Women
PLOS ONE | www.plosone.org 4 February 2014 | Volume 9 | Issue 2 | e89857
old at home, and with decrease in socioprofessional category. It
was also strongly associated with place of birth, with a North-
South gradient with a lower seropositivity rate in the North.
Having Metropolitan France as a geographic origin, having a
higher socioeconomic status and no children were predictive
factors of lower seropositivity rates. These risk factors confirm
those described in the literature. Major disparities in seropreva-
lence rates according to geographic origin could be related to
differences in breastfeeding frequency and duration [25], hygiene
level during childhood, propensity to have children that attend
day-care centers and sexual behavior [17]. Geographic origin was
recorded using medical records taken during pregnancy and was
primarily collected in order to assess the risk of ethnicity-related
diseases. Consequently, a woman, for example, of African origin
could be born in France to African parents or in Africa. It is
therefore difficult to assess if high seropositivity in women of
African origin is due to place of birth or to ethnicity.
The association between high socioeconomic status and low
seropositivity rate may be due to more hygienic living conditions in
less crowded households with less exposure to young children due
to birth control. Moreover, since a frequently described key risk
factor for seroconversion is being a parent of a child who is
shedding CMV, the tendency for primiparous women to not be
seropositive is not surprising.
Unlike in other studies, no linear relationship between age and
seropositivity for CMV was found [10,26]. This was attributable to
the fact that pregnant adolescent and young women in the age
group 15–29 years had a much higher rate of CMV seropositivity
than other age groups. Further analysis of this age group showed
that those women had a significantly lower socioeconomic status
and were less likely than the rest of the cohort to have
Metropolitan France as a geographic origin, which could explain
their high seroprevalence (data not shown). Fowler et al reported
higher seroconversion rates n during pregnancy for women#25
years compared with the general population [17].
These results clearly show that not every woman in France is at
the same risk of CMV infection. Indeed, it is very likely that if
women with certain predictive factors are seropositive for CMV at
95%, a vaccine preventing recurrent infections may not be cost-
effective, because it will probably cost a lot for a little improvement
of health in that population. In a context where the French High
Authority for Health requires a cost-effectiveness analysis when a
new health product shows an improvement in the medical benefit
and is likely to have a significant impact on the social security’s
health expenditure, (De´cret nu 2012–1116 du 2 octobre 2012
relatif aux missions me´dico-e´conomiques de la Haute Autorite´ de
sante´), a universal immunization, for example, at the beginning of
the reproductive lives of women, as for HPV vaccine, might not be
the most efficient measure to fight CMV infections in all French
diversified sub-populations. Use of serological screening and
predictive factors such as Metropolitan France origin and low
gravidity, to identify susceptible women might be less costly and
should be further explored in a comprehensive cost-effectiveness
analysis. Money saved could be reallocated to other types of
primary prevention that have been shown to actually improve
clinical outcomes like education for health of both women and
health care workers, and hygiene counseling [27,28].
In 2010, 81.7% of 820,000 births were to mothers born in
Metropolitan France, and approximately 80% were their first or
second born (INSEE, 2010 http://www.insee.fr/Statistiques des
naissances 2010). This is probably the population that should be
primarily targeted for vaccine use. However, since prevalence of
CMV infection is tending to decrease, women not primarily
targeted for anti-CMV vaccination might have a decreasing
seroprevalence in the future and be in need of immunity
[18,29,30].
However, our results should probably be confirmed by a
national sero-epidemiological study with results on both seroprev-
alence and predictive factors of the CMV infection. And, further
research is needed to estimate, based on effectiveness and cost-
effectiveness outcomes, the threshold of the global seroprevalence
at which routine vaccination for every woman in France would
become an effective strategy.
Conclusions
In conclusion, in a large prospective study conducted in
pregnant women, the proportion of pregnant women susceptible
to CMV seroconversion was high among those whose geographic
origin was Metropolitan France and whose gravidity was low. This
is the population that should be targeted for CMV prevention in
general and for a potential CMV vaccination strategy.
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